N@N

Market Maker Surveillance Report. HMPR, NGNM, TGAL, PPHM, ECTE, CELGZ, Winning Stocks With Lowest Price Friction For Tuesday,

September 25, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3723 companies with "abnormal" market making, 1739 companies with positive Friction Factors and 4112 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Hampton Roads Bankshares Inc (NASDAQ:HMPR), Neogenomics Inc (OTCBB:NGNM), Tegal Corp (NASDAQ:TGAL), Peregrine Pharmaceuticals Inc (NASDAQ:PPHM), Echo Therapeutics Inc (NASDAQ:ECTE), Celgene Corp (NASDAQ:CELGZ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  HMPR    $0.190    12.26%    125,163      62.10%    76,395       37.90%    48,768       2,567   
  NGNM    $0.430    15.87%    139,040      39.45%    132,956      37.72%    6,084        141     
  TGAL    $0.440    14.33%    46,649       63.08%    26,644       36.03%    20,005       455     
  PPHM    $0.550    47.41%    30,821,587   55.56%    24,635,171   44.41%    6,186,416    112,480 
  ECTE    $0.260    17.11%    163,421      63.00%    95,961       37.00%    67,460       2,595   
  CELGZ   $0.340    13.60%    50,450       54.25%    42,444       45.64%    8,006        235     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows HMPR with a dollar gain Tuesday of $0.19000 and a Friction Factor of 2,567 shares. That means that it only took 2,567 more shares of buying than selling to move HMPR higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

Hampton Roads Bankshares Inc (NASDAQ:HMPR) - Hampton Roads Bankshares, Inc. operates as the holding company for Bank of Hampton Roads (BOHR) and Shore Bank that provide community and commercial banking services primarily to individuals and businesses. The company offers a range of interest-bearing and non-interest-bearing deposit accounts, including commercial and retail checking accounts, money market accounts, individual retirement accounts, regular interest bearing savings accounts, and certificates of deposit. Its loan portfolio comprises commercial loans, construction loans, real estate-commercial mortgage loans, real estate-residential mortgage loans, and installment loans to individuals, as well as loans to businesses for working capital, plant expansion, and equipment purchases. It also offers telephone banking, Internet banking, remote deposit capture, automatic teller machine (ATM), and debit card services. In addition, the company provides other banking-related products and services, such as travelers checks, coin counters, wire services, and safe deposit box services. Further, it offers securities, brokerage, and investment advisory services; wealth management products and services, including stocks, bonds, annuities, mutual funds, and financial consultation; title insurance; and insurance products. BOHR operates 28 full-service offices in the Hampton Roads region of southeastern Virginia, and 24 full-service offices located in the Northeastern, Southeastern, and Research Triangle regions of North Carolina and in Richmond, Virginia; and Shore Bank operates 8 full-service offices and 1 investment center located on the Delmarva Peninsula. The company operates a network of 72 ATM machines. Hampton Roads Bankshares, Inc. was founded in 1961 and is based in Norfolk, Virginia..

Neogenomics Inc (OTCBB:NGNM) - NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the Caribbean. It focuses on cancer genetic diagnostic, prognostic, and predictive testing services. The company provides various testing services, including cytogenetics testing, which analyzes human chromosomes; Fluorescence In-Situ Hybridization (FISH) testing that analyzes abnormalities at the chromosomal and gene levels; flow cytometry testing, which analyzes gene expression of specific markers inside cells and on cell surfaces; immunohistochemistry testing that analyzes the distribution of tumor antigens in specific cell and tissue types; and molecular testing, which involves in the analysis of DNA and RNA to diagnose and predict the clinical significance of various genetic sequence disorders. It provides its services to pathologists and oncologists that perform bone marrow and/or peripheral blood sampling for the diagnosis of blood and lymphoid tumors and archival tissue referred for analysis of solid tumors, such as breast cancer; and community-based urologists by providing a FISH-based genetic test for the diagnosis of bladder cancer and early detection of recurrent disease. The company markets clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories. NeoGenomics was founded in 2001 and is headquartered in Fort Myers, Florida..

Tegal Corp (NASDAQ:TGAL) - Tegal Corporation focuses on the development and application of technologies in the field of green energy. The company, through sequel Power, engages in the promotion of large scale solar power plant development projects worldwide, as well as in the development of businesses from such projects, including supporting, developing, building, and operating solar photovoltaic fabrication facilities and solar farms and other non-PV based renewable energy projects. The company was founded in 1972 and is headquartered in Petaluma, California..

Peregrine Pharmaceuticals Inc (NASDAQ:PPHM) - Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and manufacture of monoclonal antibodies for the treatment of cancer and viral infections. The company develops clinical programs with its novel compounds bavituximab and Cotara, which are the clinical candidates under its anti-phosphatidylserine therapeutics and tumor necrosis therapy platforms. Its pipeline products comprise Bavituximab Plus Docetaxel, and Bavituximab plus carboplatin and paclitaxel, which are Phase II clinical trial products for treating advanced breast cancer patients; and Bavituximab plus carboplatin and paclitaxel, a Phase II clinical trial product for the treatment of non-small cell lung cancer, as well as Bavituximab, which is in Phase I monotherapy repeat dose safety study for treating solid tumor cancers, and in Phase Ib repeat dose safety study for the treatment of chronic hepatitis C virus infection co-infected with HIV. In addition, its pipeline products include Cotara, a product in Phase II, as well as a dosimetry and dose confirmation study for the treatment of glioblastoma multiforme, an aggressive form of brain cancer. Further, Peregrine, through its wholly owned subsidiary, Avid Bioservices, Inc., provides contract manufacturing services for biotechnology and biopharmaceutical companies, from pre-clinical drug supplies up through commercial-scale drug manufacture. Further, it provides services in support of Peregrine's product pipeline, including manufacture and scale-up of pre-clinical and clinical drug supplies. The company was founded in 1981 and is based in Tustin, California..

Echo Therapeutics Inc (NASDAQ:ECTE) - Echo Therapeutics, Inc., a medical device and specialty pharmaceutical company, engages in developing a non-invasive, wireless, and transdermal continuous glucose monitoring (tCGM) system for use in clinical settings and for people with diabetes, as well as a range of transdermal reformulations of specialty pharmaceutical products previously approved by the United States Food and Drug Administration (FDA). The company involves in developing its needle-free Prelude SkinPrep System (Prelude) for transdermal drug delivery, including topical lidocaine; and Symphony tCGM system (Symphony), a wireless and transdermal continuous glucose monitoring system designed to provide real-time blood glucose data. Its specialty pharmaceuticals pipeline is based on AzoneTS, a nontoxic, nonirritating skin penetration enhancer to enable topical application of FDA-approved prescription medications. The companys specialty pharmaceuticals include Durhalieve, an AzoneTS formulation of triamcinolone acetonide for the treatment of corticosteroid-responsive dermatoses. It has licensing agreements with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude for skin preparation prior to a range of needle-based medical procedures in North America and the United Kingdom; and Handok Pharmaceuticals Co., Ltd. for developing, marketing, selling, and distributing Symphony to medical facilities and diabetics in South Korea. The company was founded in 1989 and is based in Franklin, Massachusetts..

Celgene Corp (NASDAQ:CELGZ) - Celgene Corporation discovers, develops, and commercializes innovative therapies to treat cancer and immune-inflammatory diseases in the United States, Europe, and internationally. Its commercial stage products include REVLIMID for the treatment in combination with dexamethasone for multiple myeloma patients, as well as patients with transfusion-dependent anemia; and THALOMID to treat, in combination with dexamethasone, patients with newly diagnosed multiple myeloma, as well as for the prevention and suppression of cutaneous manifestations of erythema nodosum leprosum recurrence. The company also sells VIDAZA, used to subtypes of myelodysplastic syndromes; RITALIN to treat attention deficit hyperactivity disorder; FOCALIN to prevent oncology-related disorders; and ALKERAN to treat multiple myeloma and carcinoma of the ovary. Its development stage products consist of CC-4047, which is in Phase I and Phase II clinical trials for treating disease indications, including sickle cell anemia, myelofibrosis, and multiple myeloma; CC-10004, a Phase II clinical trial product for psoriasis and psoriatic arthritis; CC-11050, a Phase I clinical trial completed product for inflammatory conditions; CC-401, a Phase I clinical trial completed product to identify kinases that regulate pathways critical in inflammation and oncology; CC-930, a Phase Ib clinicial trial completed product for fibrotic conditions; and Amrubicin, a Phase III clinical trial product for small cell lung cancer treatment. In addition, the company is researching stem cells derived from the human placenta, as well as from the umbilical cord. Celgene Corporation has strategic collaborations with Acceleron Pharma, Inc. and Agios Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey..

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net